COST-EFFECTIVENESS OF RIVAROXABAN COMPARED WITH REAL-WORLD TREATMENT FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION IN CHINA

被引：0
|
作者：
Yang, L. [1 ]
Wu, J. [2 ]
机构：
[1] Peking Univ, Beijing, Peoples R China
[2] Bayer Healthcare Co Ltd, Beijing, Peoples R China
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.04.381
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV60
引用
收藏
页码：S63 / S63
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness of rivaroxaban versus warfarin in non-valvular atrial fibrillation patients with chronic kidney disease in China
    Liu, Lin
    Hong, Dongsheng
    Ma, Kuifen
    Lu, Xiaoyang
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2021, 46 (03) : 658 - 668
  • [32] COST-EFFECTIVENESS OF RIVAROXABAN VERSUS ACENOCUMAROL IN THE STROKE PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILATION IN THE SPANISH SETTING
    Restovic, G.
    Carcedo, D.
    McLeod, E. J.
    Guillermin, A. L. G.
    Evers, T.
    VALUE IN HEALTH, 2012, 15 (07) : A375 - A375
  • [33] Comparative cost-effectiveness of oral anticoagulants for stroke prevention in non-valvular atrial fibrillation patients in the UK
    Lip, G. Y. H.
    Lanitis, T.
    Kongnakorn, T.
    Phatak, H.
    Liu, L.
    Lawrence, J.
    Dorian, P.
    EUROPEAN HEART JOURNAL, 2015, 36 : 864 - 864
  • [34] Real-World Data of Anticoagulant Treatment in Non-valvular Atrial Fibrillation
    Calderon, Jose Miguel
    Martinez, Fernando
    Diaz, Javier
    Fernandez, Antonio
    Sauri, Inmaculada
    Uso, Ruth
    Trillo, Jose Luis
    Vela, Sara
    Bea, Carlos
    Redon, Josep
    Forner, Maria Jose
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 8
  • [35] Cost-effectiveness of Dabigatran Compared With Rivaroxaban for Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in China
    Dong, Shu-Jie
    Wu, Bin
    Zhai, Suo-Di
    Zhang, Yan-Jun
    Chu, Yun-Bo
    Gupta, Parul
    Li, Ya-Huei
    CLINICAL THERAPEUTICS, 2020, 42 (01) : 144 - 156
  • [36] Cost-effectiveness of warfarin: Trial versus "real-world" stroke prevention in atrial fibrillation
    Sorensen, Sonja V.
    Dewilde, Sarah
    Singer, Daniel E.
    Goldhaber, Samuel Z.
    Monz, Brigitta U.
    Plumb, Jonathan M.
    AMERICAN HEART JOURNAL, 2009, 157 (06) : 1064 - 1073
  • [37] Cost-effectiveness of Dabigatran and Rivaroxaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation
    Wang, Ye
    Xie, Feng
    Kong, Ming Chai
    Lee, Lai Heng
    Ng, Heng Joo
    Ko, Yu
    CARDIOVASCULAR DRUGS AND THERAPY, 2014, 28 (06) : 575 - 585
  • [38] Cost-effectiveness of Dabigatran and Rivaroxaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation
    Ye Wang
    Feng Xie
    Ming Chai Kong
    Lai Heng Lee
    Heng Joo Ng
    Yu Ko
    Cardiovascular Drugs and Therapy, 2014, 28 : 575 - 585
  • [39] Real-world effectiveness of stroke prevention in patients with non-valvular atrial fibrillation treated with rivaroxaban vs. phenprocoumon in Germany - insights from the reload study
    Bonnemeier, H.
    Mundhenke, M.
    Von Mach, T.
    Huelsebeck, M.
    EUROPEAN HEART JOURNAL, 2017, 38 : 765 - 765
  • [40] Rivaroxaban for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation and Active Cancer
    Laube, Eva Simona
    Yu, Anthony
    Gupta, Dipti
    Miao, Yimei
    Samedy, Patrick
    Wills, Jonathan
    Harnicar, Stephen J.
    Soff, Gerald A.
    Mantha, Simon
    BLOOD, 2016, 128 (22)
12345